Introduction {#sec1-1}
============

It is well-known that *Helicobacter pylori* (*H. pylori*) infection causes chronic active gastritis in all colonized subjects (Malfertheiner et al., 2017). This bacterium is responsible for the majority of peptic ulcer disease as well as gastric cancer (GC) and has been classified as a type I carcinogen since 1994 (Uemura et al., 2001; Suerbaum and Michetti, 2002). At present, *H. pylori* infection is considered an infectious disease irrespective of an individual's symptoms and stage of disease as successful eradication cures gastritis and can alter the progression to long-term complications, or recurrence of disease(Sugano et al., 2015). Although *H. pylori* prevalence is decreasing in developed countries and some developing countries, the prevalence in Asia is estimated about 54.7%, and there is a wide variation in prevalence between regions and countries (Hooi et al., 2017). The Southeast Asia region is critically important from the global health perspective as it suffers from high burdens of communicable and non-communicable diseases against a background of relatively poor health infrastructure (Narain and Bhatia, 2010). Despite of rapid economic growth and development during the last couple of decades, many countries in the region still have a high burden of communicable diseases (Gupta and Guin, 2010). However, there have been very limited data published in English about the current situation of *H. pylori* infection in countries belonging to the region and we are aware of some important data which have been reported in local languages. Therefore, expert survey is an important channel of information and may serve as a preliminary platform for further international and regional collaboration work.

Materials and Methods {#sec1-2}
=====================

This study was a survey among 26 experts from 9 Southeast Asian countries including Thailand, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore and Vietnam who attended a meeting to develop the ASEAN consensus on *H. pylori* management in Bangkok in November 2015. The representative experts were invited based on their significant contributions to the field of *H. pylori* research in their countries and via collaboration activities among national societies of gastroenterology in the region. The experts' names and their affiliations are listed in the acknowledgements section. A questionnaire was sent to each member before the consensus meeting ([Table 1](#T1){ref-type="table"}). At the meeting, the collected information were presented, intensively discussed and then finalized by all experts.

###### 

Questionnaire for Expert Opinion Survey on *H. pylori* Infection and Related Gastrointestinal Diseases in Southeast Asian Countries

  1\. What is the estimated proportion of area with limited health care facilities for *H. pylori* management in your country?
  ----------------------------------------------------------------------------------------------------------------------------------------------
   Less than 10%
   About 10-25%
   About 25-50%
   More than 50%
   More than 80%
  2\. What is the estimated prevalence of *H. pylori* infection in your country?
  3\. In your country, what are the *H. pylori* infection rates in:
  ·  Duodenal ulcer
  ·  Gastric ulcer
  ·  Non-ulcer dyspepsia / gastritis
  · Gastric cancer
  4\. Which diagnostic methods for *H. pylori* infection are mostly used in your country before treatment? (Please choose one or more answers)
   Serology test
   Stool antigen test
   Urea breath test
   Rapid urease test
   None
  5\. Do you use the test-and-treat strategy in dyspeptic patients without alarm symptoms?
   Yes (please specify which diagnostic test)
   No
  6\. What percentage of patients with endoscopic gastritis do you perform rapid urease test?
  7\. What percentage of patients with endoscopic gastritis do you take biopsy for histology?
  8\. What is the prevalence of gastric cancer in your country?
  9\. Is there any gastric cancer screening program in your country? How?
  10\. Who do you consider to have high risk and should undergo gastric cancer screening in your country?
  11\. What stage does the majority of patients with gastric cancer in your country present with?

Results {#sec1-3}
=======

The proportion of area with limited health care facilities for *H. pylori* management in Southeast Asian countries significantly varied, ranging from less than 10% in Malaysia and Singapore, 10 -- 50% in Laos, Indonesia and Thailand, 50 -- 80% in Myanmar, Philippines and Vietnam and more than 80% in Cambodia. The prevalence of *H. pylori* infection was significantly different among countries and so were the rates of infection in related gastrointestinal diseases ([Table 2](#T2){ref-type="table"}). *H. pylori* prevalence was lowest in Malaysia (20%) and highest in Myanmar (68%).

###### 

Estimated *H. pylori* Prevalence and the Infection Rates in Related Gastrointestinal Diseases in Southeast Asian Countries

  Country                                                                                           Cambodia   Indonesia   Laos   Malaysia   Myanmar   Philippines   Singapore   Thailand    Vietnam
  ------------------------------------------------------------------------------------------------- ---------- ----------- ------ ---------- --------- ------------- ----------- ----------- ---------
  *H. pylori* prevalence (%)                                                                        45         22.1        68.7   20         69        34            31          40          60
  *[†](#t2f1){ref-type="table-fn"}H. pylori* infection rates in related gastrointestinal diseases                                                                                            
   NUD/gastritis (%)                                                                                45         60          90     29         33.3      49.1          NA          23.0-61.0   54
   Duodenal ulcer (%)                                                                               90         90          79     69.8       57.1      33.5          NA          48.0-90.0   92.5
   Gastric ulcer (%)                                                                                70         80          78     56.8       57.1      36.5          NA          39.0-80.0   84
   Gastric cancer (%)                                                                               NA         NA          16     37         \> 20.0   36            NA          34.0-90.0   80

NUD, Non-ulcer dyspepsia, NA, data not available,

, Different responses among Thai experts

Regarding the diagnostic methods before treatment, rapid urease test (RUT) was the most common method, followed by urea breath test ([Table 3](#T3){ref-type="table"}). The test-and-treat strategy for dyspeptic patients without alarming symptoms was applied in most Southeast Asian countries except for Laos and Philippines. Stool antigen and urea breath tests were commonly used for this purpose. For patients undergoing upper gastrointestinal endoscopy who had the findings of endoscopic gastritis, RUT and histology were performed with significantly different proportions among countries as well as among health centers and regions within the same country. In Indonesia, the practical approaches were different between government and private hospitals with more histology examinations performed in the private settings, which was partially explained by the reimbursement policy in this country.

###### 

Practical Approaches to *H. pylori* Diagnosis and Management in Southeast Asian Countries

  Country                                                                                                 Cambodia        Indonesia                         Laos   Malaysia   Myanmar         Philippines   Singapore   Thailand                                Vietnam
  ------------------------------------------------------------------------------------------------------- --------------- --------------------------------- ------ ---------- --------------- ------------- ----------- --------------------------------------- ---------
  Most common test for *H. pylori* diagnosis before treatment                                                                                                                                                                                                   
   Serology                                                                                               \+              \+                                \-     \+         \-              \+            \-          \-                                      \+
   Stool Ag test                                                                                          \+              \-                                \-     \+         \+              \+            \-          \-                                      \-
   UBT                                                                                                    \-              \+                                \-     \+         \+              \+            \+          \+                                      \+
   RUT                                                                                                    \+              \+                                \+     \+         \+              \+            \+          \+                                      \+
  Test-and-Treat strategy using non-invasive test for *H. pylori* in patients without alarming symptoms                                                                                                                                                         
   Test-and-treat                                                                                         Yes             Yes                               No     Yes        Yes             No            No          Yes/No[†](#t3f1){ref-type="table-fn"}   Yes
   Type of test                                                                                           Stool Ag test   UBT                               \-     UBT        Stool Ag test   \-            \-          UBT                                     UBT
  Practical approach for *H. pylori* diagnosis for patients with endoscopic gastritis                                                                                                                                                                           
   RUT (%)                                                                                                10              [‡](#t3f2){ref-type="table-fn"}   30     100        90              100           \> 95.0     \> 90.0                                 \> 90.0
   Histology (%)                                                                                          100             [§](#t3f3){ref-type="table-fn"}   70     100        50              10            \> 95.0     [¶](#t3f4){ref-type="table-fn"}         10

UBT, Urea breath test; RUT, Rapid urease test via upper gastrointestinal endoscopy;

Majority of experts prefer not to use the test-and-treat strategy in Thailand;

, 20% (government hospital) and 60 -- 80% (private hospital);

, 80% (government hospital) and 20 -- 90% (private hospital);

, Significant varies responses from 0% to 100%.

The prevalence of GC in each country in comparison with the *H. pylori* prevalence in each population is summarized in [Figure 1](#F1){ref-type="fig"}. It was highest in Vietnam (17/100.000) and lowest in Indonesia (1/100.000). Familial history of GC and precancerous gastric lesions were commonly considered as high-risk factors of GC development ([Table 4](#T4){ref-type="table"}). In multi-ethnic countries, some ethnic groups including Chinese, Batak and Minahasanese were considered as having higher risk. However, there have been no national screening programs for GC in all countries, and a majority of patients with GC were diagnosed in advanced stages with very poor 5-year survival.

###### 

Current Screening Program, Surveillance Strategy and Prognosis of Gastric Cancer in Southeast Asian Countries

  Country                                                                                       Cambodia   Indonesia                           Laos       Malaysia                            Myanmar    Philippines   Singapore   Thailand   Vietnam
  --------------------------------------------------------------------------------------------- ---------- ----------------------------------- ---------- ----------------------------------- ---------- ------------- ----------- ---------- ----------
  National screening program                                                                    No         No                                  No         No                                  No         No            No          No         No
  Gastric cancer stage and prognosis                                                                                                                                                                                                          
   Stage at diagnosis in majority of patients                                                   Advanced   Advanced                            Advanced   Advanced                            Advanced   Advanced      Advanced    Advanced   Advanced
   5-year survival rate (%)                                                                     NA         \< 10.0                             NA         NA                                  NA         11.6          26          \< 20.0    \`10.0
  Individuals considered as high-risk patients of gastric cancer and should undergo screening                                                                                                                                                 
   Ethnicity                                                                                    \-         \+[a](#t4f1){ref-type="table-fn"}   \-         \+[b](#t4f2){ref-type="table-fn"}   \-         \-            \-          \-         \-
   Elderly                                                                                      \-         \-                                  \+         \-                                  \+         \-            \-          \+         \+
   Precancerous GC lesions                                                                      \-         \-                                  \+         \-                                  \-         \+            \+          \+         \+
   Family history of GC                                                                         \+         \-                                  \+         \-                                  \+         \+            \-          \+         \+
   *H. pylori* infection                                                                        \-         \-                                  \-         \-                                  \-         \+            \-          \-         \-
   Gastric ulcer                                                                                \+         \-                                  \+         \-                                  \-         \-            \-          \-         \-
   Hx of gastrectomy                                                                            \-         \-                                  \+         \-                                  \-         \-            \-          \-         \-
   Pepsinogen test (+)                                                                          \-         \-                                  \-         \-                                  \-         \-            \-          \-         \-

GC, gastric cancer; Hx, history; NA, data not available;

, Chinese, Batak, Minahasanese;

, Chinese
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Discussion {#sec1-4}
==========

Our study showed that the prevalence of *H. pylori* infection was strikingly different among countries in the Southeast Asian region. Besides the genetic diversity of *H. pylori*, environmental factors (i.e. socioeconomic status, diet and smoking) and host genetic susceptibility have been reported to be related to the infection outcome (Correa and Piazuelo, 2008). Multi-ethnicity is one of the common and interesting characteristics of many countries in the region. Recent collaboration studies among Southeast Asian countries have shed light on the interactions among these above-mentioned factors. Population-based cross-sectional studies in Indonesia and Vietnam showed that variations in geographical region and ethnicity were independent factors associated with the risk of *H. pylori* acquisition (Syam et al., 2015; Binh et al., 2018).

This survey showed that the rates of *H. pylori* infection in relation to upper gastrointestinal diseases were also significantly different among countries in the region ([Table 2](#T2){ref-type="table"}). The infection rate in patients with peptic ulcer disease was about one third in Philippines, two third in Malaysia, and more than two third of patients in the rest countries with available data. A previous meta-analysis in Southeast Asian countries showed that patients infected with vacA m1 type or cagA-positive strains had an increased risk of peptic ulcer disease and there was a significant variation in the frequencies of cagA status and vacA genotypes among countries and the individual races residing within each respective country (Sahara et al., 2012). A recent study in Vietnam, a multi-ethnic country in the region, showed that the E-De ethnic group living in the high plateau region of central Vietnam carried strains with Western-type CagA (82%) and exhibited significantly lower gastric mucosal inflammation compared to other ethnic groups. But the histological scores of Western-type CagA and East-Asian-type CagA within the E-De group showed no significant differences (Binh et al., 2018). Therefore, host factors are likely to be important determinants in addition to bacterial virulence factors for gastric mucosal inflammation and contribute to the Asian enigma.

Regarding GC, Vietnam has the highest prevalence of GC among Southeast Asian countries. The majority (97%) of strains in Vietnam was East-Asian type cagA, whereas only about half of the strains in Thailand and Malaysia was East-Asian type cagA and 94.1% of the strains in Myanmar was Western-type cagA strains (Sahara et al., 2012; Myint et al., 2018). One another interesting result was the significantly high proportion of *H. pylori*-negative GC. The *H. pylori* infection rate in patients with GC was reported 16% in Laos, 80% in Vietnam and raging from 34 to 90% in Thailand. This could raise a concern about the reliability of diagnostic methods for *H. pylori* infection. The worldwide proportion rate of *H. pylori*-negative GC according to recent reports is about 0.4--5.4% (Yamamoto et al., 2015). The minimum criteria for this diagnosis include negative findings in two or more methods (endoscopic, pathological, serum pepsinogen test), negative UBT or serum IgG test and no history of *H. pylori* eradication (Yamamoto et al., 2015). There have been so far no studies in the Southeast Asian region applying the strict criteria. The data were collected from experts' experience during their clinical practice with great variants. Two recent studies used a combination of several tests (culture, histology, RUT and serum *H. pylori* antibody test) showed that 17.0% of GC patients in Thailand and 20.6% of GC patients in Vietnam had negative results for all four tests (Vilaichone et al., 2014; Binh et al., 2017). In addition, the rate of unintended *H. pylori* eradication in the Vietnamese was about 11%, which is similar to that in the Japanese (Ono et al., 2012; Boda et al., 2014; Hiyama et al., 2015). Therefore, the rate of *H. pylori*-negative GC in the region may be higher compared to the literature. Other environmental factors may play important roles in the development of GC, which should be investigated by applying the strict criteria.

This study has some limitations. First, it is a survey of expert opinions and there are limited strong evidence to support the data. Second, the methodology for the diagnosis of *H. pylori* infection used in local studies could be heterogeneous and, therefore, may not reflect the true picture.

In summary, there were significant differences in *H. pylori* acquirement and the infection rates in patients with gastritis, peptic ulcer diseases and GC among Southeast Asian countries. No countries in the region have national screening program for GC, and the prognosis of patients with GC is very poor. The result of this survey is a platform for future international and regional research collaboration.
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